Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

OBJECTIVES To determine whether the serum concentration of BPSA, a distinct form of free prostate-specific antigen (PSA) enriched in the nodular transition zone (TZ) tissue of benign prostatic hyperplasia (BPH), can predict TZ volume and diagnose BPH-associated prostatic enlargement in patients without prostate cancer. METHODS We studied 91 consecutive patients without prostate cancer who underwent a 10-core or greater biopsy of the prostate. The associations between prostate volume, age, International Prostate Symptom Score, and serum concentrations of PSA, free PSA, and BPSA were evaluated by receiver operating characteristic curve and linear and binary logistic regression analyses. RESULTS BPSA and free PSA showed stronger correlations with both age (BPSA = 0.38, free PSA = 0.40, PSA = 0.24) and TZ volume (BPSA = 0.67, free PSA = 0.64, PSA = 0.55) than did PSA. The percent free PSA had no statistically significant correlation with TZ volume (P = 0.08). Subtraction of BPSA from free PSA reduced its correlation with TZ volume to below that of PSA (from 0.64 to 0.48). Linear regression analyses showed that, unlike PSA, both BPSA and free PSA displayed an age-independent relationship to TZ volume. The receiver operating characteristic curve (for TZ greater than 30 cm3) and binary logistic regression analyses showed that BPSA (area under the curve = 0.844) outperformed both free PSA (area under the curve = 0.799) and PSA (area under the curve = 0.749) in its ability to predict clinically significant TZ enlargement. CONCLUSIONS In patients without prostate cancer, the serum concentration of BPSA displayed an age-independent, log-linear relationship to TZ volume and was a better predictor of prostatic enlargement than either PSA or free PSA. BPSA may also predict clinical parameters of BPH and is under evaluation as a marker of BPH progression and response to therapy.

[1]  A. Haese*,et al.  Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. , 1997, The Journal of urology.

[2]  K. Slawin,et al.  Seminal plasma contains “BPSA,” a molecular form of prostate‐specific antigen that is associated with benign prostatic hyperplasia , 2000, The Prostate.

[3]  R. Roberts,et al.  Natural history of prostatism: risk factors for acute urinary retention. , 1997, The Journal of urology.

[4]  C. Roehrborn,et al.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. , 1999, Urology.

[5]  R. Wolfert,et al.  A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. , 1997, Urology.

[6]  P. Schellhammer,et al.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. , 2000, The Journal of urology.

[7]  R. Wolfert,et al.  "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. , 2000, Urology.

[8]  J. McNeal.  Origin and evolution of benign prostatic enlargement. , 1978, Investigative urology.

[9]  G. Bartsch,et al.  Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer , 1999, The Prostate.

[10]  P. Boyle,et al.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. , 1999, Urology.

[11]  S. Loening,et al.  The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia , 1997, Cancer.

[12]  H. Klocker,et al.  Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. , 2003, Urology.

[13]  T. Wheeler,et al.  A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. , 2000, Cancer research.

[14]  J. Morote,et al.  Prediction of Prostate Volume Based on Total and Free Serum Prostate–Specific Antigen: Is It Reliable? , 2000, European Urology.

[15]  P. Carpenter,et al.  A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. , 2001, Cancer research.

[16]  Leonard S Marks,et al.  Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. , 2003, Clinical chemistry.

[17]  K. Slawin,et al.  Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. , 2000, European journal of biochemistry.

[18]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.